Autor según el artículo: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier
Departamento: Ciències Mèdiques Bàsiques Bioquímica i Biotecnologia
Autor/es de la URV: Avilés Jurado, Francisco Javier / Terra Barbadora, Ximena
Palabras clave: Tumor recurrence Tumor marker Tobacco use Retrospective study Retrospective studies Recursive partitioning Radiotherapy Prognostic factor Prognosis Primary tumor Practice guideline Neoplasm recurrence, local Multimodality cancer therapy Middle aged Male Major clinical study Local recurrence free survival Humans Human Hematological parameters Head and neck tumor Head and neck squamous cell carcinoma Head and neck neoplasms Follow up Female Disease specific survival Disease control Controlled study Cohort analysis Cisplatin Chemoradiotherapy Cetuximab Carcinoma Carboplatin Cancer surgery Cancer staging Cancer risk Cancer classification Biomarkers, tumor Ast/alt (deritis) ratio Ast Aspartic acid Aspartate aminotransferases Aspartate aminotransferase Aspartate aminotransaminase Article Alt (deritis) ratio Alanine transaminase Alanine aminotransferase Alanine aminotransaminase Alanine Adult
Resumen: Background The aim of this study is to evaluate the relationship between the aspartate aminotransaminase (AST) and alanine aminotransaminase (ALT) ratio and local disease control in patients with head and neck squamous cell carcinomas (HNSCC) treated with radiotherapy/chemoradiotherapy.
Methods We calculated the pre-treatment AST/ALT ratio in 670 patients with HNSCC treated with radiotherapy (n = 309, 46.1%) or chemoradiotherapy (n = 361, 53.9%).
Results Five-year local recurrence-free survival for patients with a low AST/ALT ratio value (n = 529, 79.0%) was 75.0% (95% CI: 71.1-78.9), and for patients with a high value (n = 141, 21.0%) it was 53.4% (CI 95: 44.4-62.4) (p = 0.0001). In a multivariable analysis, patients with a high ratio had nearly twice the risk of having a local tumor recurrence (HR 1.97, 95% CI 1.42-2.75, p = 0.0001).
Conclusion The AST/ALT ratio was independently associated with the risk of local recurrence in patients with HNSCC treated with radiotherapy or chemoradiotherapy.
Áreas temáticas: Surgery Saúde coletiva Otorhinolaryngology Odontología Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias iv Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: franciscojavier.aviles@urv.cat ximena.terra@urv.cat
Identificador del autor: 0000-0001-5560-8097 0000-0003-1043-5844
Fecha de alta del registro: 2024-10-12
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck. 43 (7): 2091-2100
Referencia de l'ítem segons les normes APA: Sansa, Aina; Venegas, Maria del Prado; Valero, Cristina; Pardo, Laura; Aviles-Jurado, Francesc-Xavier; Terra, Ximena; Quer, Miquel; Leon, Xavier (2021). The aspartate aminotransaminase/alanine aminotransaminase (De Ritis) ratio predicts sensitivity to radiotherapy in head and neck carcinoma patients. Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck, 43(7), 2091-2100. DOI: 10.1002/hed.26673
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2021
Tipo de publicación: Journal Publications
Repositori URV